Category Specific RSS

asx pxs

Syntara prepares for new clinical trials led by Professor Fiona Wood to restore elasticity into burn scars

Beyond the searing pain of burns, permanent scarring of the skin has a devastating lifelong impact on quality of life.…

2 years ago

First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease

Parkinson’s UK, in collaboration with Australian researchers, has taken a major step towards preventing the development of Parkinson’s disease with…

2 years ago

Pharmaxis accelerates clinical drug developments with additional resources via sale of mannitol business to Arna Pharma

With a burgeoning pipeline of drugs deeply advanced, clinical stage biopharmaceuticals company Pharmaxis (ASX: PXS) has streamlined its business with…

2 years ago

Garvan Institute preclinical study identifies potential of Pharmaxis drug to boost pancreatic cancer survival rate by 35%

Each year, more than 4,000 Australians are diagnosed with pancreatic cancer, a form of cancer which is difficult to diagnose…

2 years ago

Encouraged by interim data, FDA approves Pharmaxis to expand its myelofibrosis treatment trials

Fresh off reporting final interim data from their Phase 2 clinical trials for PXS-5505 to treat myelofibrosis, biotech company Pharmaxis…

2 years ago

Pharmaxis delivers impressive Phase 2 clinical data to treat myelofibrosis, pushing on to FDA discussions

In a potential breakthrough for the field of bone marrow cancer treatment, biotech company Pharmaxis (ASX: PXS) has released the…

2 years ago